Lifeward Ltd. (NASDAQ: LFWD) announced a transformative strategic partnership with Oramed Pharmaceuticals Inc. on January 13, 2026. Under the agreement, Oramed will acquire up to 49.99% equity ownership in Lifeward and provide up to approximately 47 million dollars in capital through equity, convertible notes, milestone-based funding, and warrant coverage. Lifeward will integrate Oramed's proprietary Protein Oral Delivery (POD) technology, a clinical-stage technology designed to convert injectable biological therapies into oral medications. The POD technology targets the 600 billion dollar injectable drugs market, including ORMD-0801, which aims to become the world's first commercialized oral insulin medicine. The transaction received unanimous board approval and is subject to shareholder approval. The capital is intended to support Lifeward's path to profitability while diversifying its portfolio across medical technology and biotech sectors.
Read full analysisLifeward Ltd. (NASDAQ: LFWD) announced a transformative strategic partnership with Oramed Pharmaceuticals Inc. on January 13, 2026. Under the agreement, Oramed will acquire up to 49.99% equity ownership in Lifeward and provide up to approximately 47 million dollars in capital through equity, convertible notes, milestone-based funding, and warrant coverage. Lifeward will integrate Oramed's proprietary Protein Oral Delivery (POD) technology, a clinical-stage technology designed to convert injectable biological therapies into oral medications. The POD technology targets the 600 billion dollar injectable drugs market, including ORMD-0801, which aims to become the world's first commercialized oral insulin medicine. The transaction received unanimous board approval and is subject to shareholder approval. The capital is intended to support Lifeward's path to profitability while diversifying its portfolio across medical technology and biotech sectors.
Lifeward is an Israeli-American medical technology company best known for its ReWalk exoskeleton systems that help people with spinal cord injuries walk again. In January 2026, the company announced a strategic partnership with Oramed Pharmaceuticals to diversify into oral drug delivery technology, but the stock has since given back all those gains and more. A 1-for-12 reverse split took effect last week to maintain Nasdaq listing compliance, triggering a 25%+ selloff that today's thin-volume bounce only partially reverses.